RARE Ultragenyx Pharmaceutical
- 40.340
- +0.440+1.10%
- 39.980
- -0.360-0.89%
Ultragenyx Pharmaceutical News
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Truist Financial
Buy Rating Affirmed for Ultragenyx Pharmaceutical Based on Clinical Updates and Market Valuation Disconnect
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
DALLAS, May 14, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenera
Would Ultragenyx Pharmaceutical (NASDAQ:RARE) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Analysts' Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Illumina (ILMN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $109
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical with a Buy and lowers the price target from $111 to $109.
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
Ultragenyx Pharmaceutical(RARE.US) Officer Sells US$15,455.64 in Common Stock
$Ultragenyx Pharmaceutical(RARE.US)$ Officer Crombez Eric sold 354 shares of common stock on May 2, 2024 at an average price of $43.66 for a total value of $15,455.64.Source: Announcement What is stat
Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains $107 price target.
Earnings Call Summary | Ultragenyx Pharmaceutical(RARE.US) Q1 2024 Earnings Conference
The following is a summary of the Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript:Financial Performance:Ultragenyx reported Q1 2024 revenue of $109 million, with substantial co
Ultragenyx Pharma Is Maintained at Neutral by Wedbush
Ultragenyx Pharma Is Maintained at Neutral by Wedbush
Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $47
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical with a Neutral and lowers the price target from $48 to $47.
Truist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)
Analysis
Price Target
No Data
